Literature DB >> 21165224

Penicillamine-induced Elastosis Perforans Serpiginosa and Cutis Laxa in a Patient with Wilson's Disease.

Se Young Na1, Mira Choi, Min Ji Kim, Jong Hee Lee, Soyun Cho.   

Abstract

Elastosis perforans serpiginosa (EPS) is a rare reactive perforating dermatosis that is characterized by the transepidermal elimination of abnormal elastic fibers. Penicillamine, which is one of the clear triggers for EPS, is a heavy metal chelator that is primarily used for disorders such as cystinuria and Wilson's disease. It may cause alterations in the dermal elastic tissue such as pseudo-pseudoxanthoma elasticum, acquired cutis laxa, EPS and anetoderma. Herein we present a case of cutis laxa and EPS in a 34-year-old man who was previously on a long-term, high-dose of penicillamine for Wilson's disease. The combination of EPS and cutis laxa induced by penicillamine has rarely been reported and we report the first such case in Korea.

Entities:  

Keywords:  Cutis laxa; Elastosis perforans serpiginosa; Penicillamine; Wilson's disease

Year:  2010        PMID: 21165224      PMCID: PMC2991731          DOI: 10.5021/ad.2010.22.4.468

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


  13 in total

1.  Imiquimod therapy for elastosis perforans serpiginosa.

Authors:  Susan C Kelly; Stephen M Purcell
Journal:  Arch Dermatol       Date:  2006-07

2.  Elastosis perforans serpiginosa: a review of the literature and report of 11 cases.

Authors:  A H Mehregan
Journal:  Arch Dermatol       Date:  1968-04

3.  Elastosis perforans serpiginosa during penicillamine therapy for Wilson disease.

Authors:  F Pass; S Goldfischer; I Sternlieb; I H Scheinberg
Journal:  Arch Dermatol       Date:  1973-11

4.  D-penicillamine-induced elastosis perforans serpiginosa and localized cutis laxa in a patient with Wilson's disease.

Authors:  B Amichai; A Rotem; A Metzker
Journal:  Isr J Med Sci       Date:  1994-08

5.  Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with penicillamine.

Authors:  Cécile Bécuwe; Stéphane Dalle; Sandra Ronger-Savlé; François Skowron; Brigitte Balme; Jean Kanitakis; Luc Thomas
Journal:  Dermatology       Date:  2005       Impact factor: 5.366

Review 6.  Elastosis perforans serpiginosa and associated disorders.

Authors:  R K Mehta; N P Burrows; C M Payne; S S Mendelsohn; F M Pope; E Rytina
Journal:  Clin Exp Dermatol       Date:  2001-09       Impact factor: 3.470

7.  Penicillamine-induced elastosis perforans serpiginosa. Tip of the iceberg?

Authors:  R G Price; R S Prentice
Journal:  Am J Dermatopathol       Date:  1986-08       Impact factor: 1.533

8.  Generalized elastosis perforans serpiginosa in Down's syndrome.

Authors:  B O'Donnell; P Kelly; P Dervan; F C Powell
Journal:  Clin Exp Dermatol       Date:  1992-01       Impact factor: 3.470

9.  "Lumpy-bumpy" elastic fibers in the skin and lungs of a patient with a penicillamine-induced elastosis perforans serpiginosa.

Authors:  H Bardach; W Gebhart; G Niebauer
Journal:  J Cutan Pathol       Date:  1979-08       Impact factor: 1.587

Review 10.  D-penicillamine-induced elastosis perforans serpiginosa in a child with juvenile rheumatoid arthritis. Report of a case and review of the literature.

Authors:  E E Sahn; J C Maize; P D Garen; S C Mullins; R M Silver
Journal:  J Am Acad Dermatol       Date:  1989-05       Impact factor: 11.527

View more
  3 in total

1.  Elastosis perforans serpiginosa.

Authors:  Si-Hyung Lee; Yuri Choi; Soo-Chan Kim
Journal:  Ann Dermatol       Date:  2014-02-17       Impact factor: 1.444

2.  Abdominal elastotic lesions. A clinicopathologic study of 23 cases.

Authors:  José Fernando Val-Bernal; Marta María Mayorga; Francisco Javier García-Gutierrez
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

Review 3.  The Role of Zinc in the Treatment of Wilson's Disease.

Authors:  Abolfazl Avan; Anna Członkowska; Susan Gaskin; Alberto Granzotto; Stefano L Sensi; Tjaard U Hoogenraad
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.